ENBIO CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,795 KRW | 0.00% |
|
+0.90% | -20.26% |
| 2021 | ENBIO Co., Ltd. announced that it has received KRW 20 billion in funding | CI |
| 2021 | ENBIO Co., Ltd. announced that it expects to receive KRW 20 billion in funding | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Capitalization 1 | 1,57,821 | 86,398 | 46,351 | 38,091 |
| Enterprise Value (EV) 1 | 1,58,859 | 81,635 | 52,938 | 46,216 |
| P/E ratio | -29.1 x | 23.1 x | -13.5 x | -6.04 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 4.57 x | 2.58 x | 1.35 x | 1.12 x |
| EV / Revenue | 4.6 x | 2.44 x | 1.55 x | 1.36 x |
| EV / EBITDA | 25.3 x | 23.9 x | -20.9 x | -61.9 x |
| EV / FCF | 20.1 x | -12.4 x | -4.65 x | 17 x |
| FCF Yield | 4.97% | -8.08% | -21.5% | 5.9% |
| Price to Book | 4.27 x | 1.73 x | 1 x | 0.93 x |
| Nbr of stocks (in thousands) | 10,084 | 10,868 | 10,868 | 10,868 |
| Reference price 2 | 15,650 | 7,950 | 4,265 | 3,505 |
| Announcement Date | 01/03/21 | 01/03/22 | 01/03/23 | 29/02/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net sales 1 | 34,563 | 33,466 | 34,240 | 34,024 |
| EBITDA 1 | 6,272 | 3,411 | -2,538 | -746.9 |
| EBIT 1 | 4,096 | 1,122 | -4,777 | -3,354 |
| Operating Margin | 11.85% | 3.35% | -13.95% | -9.86% |
| Earnings before Tax (EBT) 1 | -4,966 | 6,128 | -3,832 | -8,060 |
| Net income 1 | -4,449 | 5,245 | -3,445 | -6,300 |
| Net margin | -12.87% | 15.67% | -10.06% | -18.52% |
| EPS 2 | -537.8 | 344.0 | -317.0 | -580.0 |
| Free Cash Flow 1 | 7,903 | -6,597 | -11,387 | 2,726 |
| FCF margin | 22.86% | -19.71% | -33.26% | 8.01% |
| FCF Conversion (EBITDA) | 125.99% | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 01/03/21 | 01/03/22 | 01/03/23 | 29/02/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net Debt 1 | 1,038 | - | 6,587 | 8,125 |
| Net Cash position 1 | - | 4,764 | - | - |
| Leverage (Debt/EBITDA) | 0.1655 x | - | -2.595 x | -10.88 x |
| Free Cash Flow 1 | 7,903 | -6,597 | -11,387 | 2,726 |
| ROE (net income / shareholders' equity) | -13.4% | 12.1% | -7.15% | -14.4% |
| ROA (Net income/ Total Assets) | 3.83% | 0.87% | -3.36% | -2.73% |
| Assets 1 | -1,16,125 | 6,06,294 | 1,02,658 | 2,30,950 |
| Book Value Per Share 2 | 3,664 | 4,593 | 4,278 | 3,755 |
| Cash Flow per Share 2 | 875.0 | 2,057 | 1,039 | 267.0 |
| Capex 1 | 312 | 2,915 | 180 | 155 |
| Capex / Sales | 0.9% | 8.71% | 0.52% | 0.45% |
| Announcement Date | 01/03/21 | 01/03/22 | 01/03/23 | 29/02/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -20.26% | 22.18M | |
| +19.95% | 40.06B | |
| -.--% | 11.1B | |
| +7.11% | 8.43B | |
| +1.35% | 6.46B | |
| -3.19% | 6.16B | |
| -5.87% | 5.61B | |
| +37.82% | 5.46B | |
| -18.11% | 5.11B | |
| -14.56% | 4.51B |
- Stock Market
- Equities
- A352940 Stock
- Financials ENBIO Co., Ltd.
